Published Technical Disclosure Archive

Adaptive Biotherapeutic Agent Delivery Platform

Publication ID: 24-11857673_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Adaptive Biotherapeutic Agent Delivery Platform,” Published Technical Disclosure No. 24-11857673_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857673_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,673.

Summary of the Inventive Concept

A next-generation, implantable biotherapeutic agent delivery system that integrates self-healing, nanoscale, porous matrices with artificial intelligence and machine learning algorithms to optimize therapeutic outcomes.

Background and Problem Solved

The original patent's implantable cellular and biotherapeutic agent delivery canister, while innovative, has limitations in terms of adaptability to changing host environments and lack of real-time optimization. The new inventive concept addresses these limitations by incorporating adaptive nanophase morphologies, bioresorbable canisters, and AI-driven optimization.

Detailed Description of the Inventive Concept

The new inventive concept comprises a modular, implantable device featuring multiple, interconnected nanophase modules, each with unique morphology and composition tailored to specific disease states. The nanophase tubular structure is designed to adapt to changes in the host environment, releasing therapeutic metabolites in a biologically relevant environment. The system integrates artificial intelligence and machine learning algorithms to optimize therapeutic outcomes in real-time.

Novelty and Inventive Step

The new claims introduce several non-obvious features, including self-healing, nanoscale, porous matrices, bioresorbable canisters, and AI-driven optimization, which significantly depart from the original patent's design and operation.

Alternative Embodiments and Variations

Alternative embodiments may include varying the nanophase morphology and composition to target specific disease states, incorporating additional sensors or actuators to enhance real-time optimization, or developing miniaturized versions of the device for targeted delivery.

Potential Commercial Applications and Market

The new inventive concept has significant commercial potential in the fields of regenerative medicine, immunotherapy, and personalized medicine, with potential applications in treating chronic diseases such as autoimmune disorders, cancer, and cardiovascular disease.

CPC Classifications

SectionClassGroup
A A61 A61K9/0024
A A61 A61F2/022
A A61 A61K31/337
A A61 A61K31/397
A A61 A61K31/436
A A61 A61K31/65
A A61 A61K31/7036
A A61 A61K35/28
A A61 A61K38/14
A A61 A61K38/1866
A A61 A61K38/22
A A61 A61K39/395
A A61 A61K47/02
A A61 A61M39/0247
A A61 A61M2039/027
A A61 A61M2039/0261
A A61 A61M2039/0276
A A61 A61M2205/04

Field of Art

Biomedical engineering focused on implantable drug delivery systems, nanomaterials, and therapeutic agent encapsulation technologies, requiring advanced degrees in materials science, bioengineering, or related interdisciplinary fields with expertise in nanotechnology and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or materials scientist with graduate-level training, familiar with nanoporous material design, implantable medical device technologies, and advanced drug delivery mechanisms, capable of understanding complex material interactions and therapeutic agent encapsulation strategies

Obviousness Rationale

A PHOSITA would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's core nanoporous implantable device technology. The fundamental structural and functional principles of nanoscale tubular matrices for therapeutic agent delivery remain consistent, with the PTD introducing incremental improvements in adaptability, modularity, and algorithmic optimization. These variations would be considered obvious refinements within the established technological framework of the source patent.

Obvious Combinations & Variations

Source Patent Element
Apertured metallic capsule with nanophase tubular structure for fluid exchange
PTD Variation
Bioresorbable canister with self-healing nanoscale porous matrix
Obviousness Reasoning
Predictable material science evolution using known biodegradable metal alloys and nanomaterial engineering techniques, representing a routine design optimization for improved biocompatibility
Source Patent Element
Nanotubes made of medical grade metals like titanium and stainless steel
PTD Variation
Nanophase modules with tunable morphology and composition for specific disease states
Obviousness Reasoning
Known material science approach of creating application-specific nanomaterial architectures through compositional and structural modifications, representing a standard design strategy in biomedical engineering
Source Patent Element
Implantable device for cellular and biotherapeutic agent delivery
PTD Variation
Integration of artificial intelligence and machine learning algorithms for real-time therapeutic optimization
Obviousness Reasoning
Predictable technological convergence combining established medical device design with emerging computational optimization techniques, representing a natural progression in personalized medical technology
Source Patent Element
Nanoporous substrate with fluid exchange capabilities
PTD Variation
Adaptive nanoscale matrix designed to respond to host environment changes
Obviousness Reasoning
Routine materials engineering approach of developing responsive nanomaterials with dynamic interaction capabilities, representing an expected technological advancement in implantable device design
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857673 and the disclosed technological variations, a person having ordinary skill in the art would find the claimed innovations obvious and anticipated, as the PTD represents a predictable combination of known nanomaterial design principles, medical device engineering techniques, and computational optimization strategies that would be readily apparent to a skilled practitioner in the field of implantable therapeutic delivery systems.

Original Patent Information

Patent NumberUS 11,857,673
TitleImplantable cellular and biotherapeutic agent delivery canister
Assignee(s)NanoVault Medical LLC